Gamut of Patients Referred to Cardiology for Question of Clonal Hematopoiesis.

This publication reviews how clonal hematopoiesis (CH) presents in patients seen by cardiologists and how it should inform cardiovascular risk assessment and management.

Key points:

• Clinical contexts of detection: CH is identified in several settings relevant to cardio-oncology:
  • • Incidentally during evaluation for cytopenias.
  • • During workup for suspected germline cancer predisposition.
  • • In patients with coexisting malignancies.
  • • In post–cytotoxic therapy surveillance.

• Risk heterogeneity: Not all CH is equivalent. Cardiovascular risk is shaped by:
  • • Clone features: larger variant allele fraction, multiple mutations, and the presence of specific driver genes (e.g., canonical CH drivers) increase risk.
  • • Clinical context: age-related vs therapy-related CH behave differently; coexisting malignancy and prior cytotoxic exposure further modify risk.
  • • Traditional cardiovascular factors: hypertension, hyperlipidemia, diabetes, smoking, and others interact with CH to influence ischemic events.

• Cardiovascular implications: Certain CH profiles, especially high-risk genotypes and larger clones, are associated with elevated risk of ischemic cardiovascular events and hematologic progression, necessitating closer cardiometabolic surveillance.

• Practical approach proposed:
  • • Interpret CH in relation to how it was detected (incidental vs therapy-related vs malignancy-associated).
  • • Integrate genomic data (clone size, number and type of mutations) with conventional cardiovascular risk stratification.
  • • Use this integrated framework to personalize:
    • • Cardiovascular evaluation intensity.
    • • Aggressiveness of risk factor modification.
    • • Consideration for enrollment in mechanistically targeted prevention trials.

Overall, the article argues that CH should be treated as a context-dependent, genomically defined cardiovascular risk modifier and outlines how cardiologists—especially in cardio-oncology—can incorporate CH characteristics into individualized risk mitigation strategies and clinical trial design.